PE20170201A1 - Formas de dosificacion farmaceutica - Google Patents

Formas de dosificacion farmaceutica

Info

Publication number
PE20170201A1
PE20170201A1 PE2016002812A PE2016002812A PE20170201A1 PE 20170201 A1 PE20170201 A1 PE 20170201A1 PE 2016002812 A PE2016002812 A PE 2016002812A PE 2016002812 A PE2016002812 A PE 2016002812A PE 20170201 A1 PE20170201 A1 PE 20170201A1
Authority
PE
Peru
Prior art keywords
pharmaceutical dosage
dosage forms
dosage form
fluorobenzonitrile
pyrrolo
Prior art date
Application number
PE2016002812A
Other languages
English (en)
Inventor
Stefania Beato
Peggy Quinton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20170201A1 publication Critical patent/PE20170201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a una forma de dosificacion farmaceutica para administracion oral que comprende: a) 4-[(5R)-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-5-il]-3-fluorobenzonitrilo y b) al menos 30 % por peso de celulosa microcristalina respecto al total de la forma de dosificacion farmaceutica. Ademas, puede comprender manitol y un agente deslizante tal como dioxido de silicio coloidal
PE2016002812A 2014-07-07 2015-07-06 Formas de dosificacion farmaceutica PE20170201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462021271P 2014-07-07 2014-07-07

Publications (1)

Publication Number Publication Date
PE20170201A1 true PE20170201A1 (es) 2017-04-08

Family

ID=53610933

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002812A PE20170201A1 (es) 2014-07-07 2015-07-06 Formas de dosificacion farmaceutica

Country Status (29)

Country Link
US (2) US10143680B2 (es)
EP (2) EP3166596B1 (es)
JP (2) JP6731136B2 (es)
KR (1) KR102468610B1 (es)
CN (1) CN106470704B (es)
AR (1) AR101116A1 (es)
AU (1) AU2015287336B2 (es)
BR (1) BR112016030243B1 (es)
CA (1) CA2954393C (es)
CL (1) CL2017000026A1 (es)
CY (1) CY1120749T1 (es)
DK (1) DK3166596T3 (es)
EA (2) EA033685B1 (es)
EC (1) ECSP17008187A (es)
ES (1) ES2686704T3 (es)
HR (1) HRP20181406T1 (es)
HU (1) HUE039037T2 (es)
IL (1) IL249374B (es)
LT (1) LT3166596T (es)
MX (1) MX2016017315A (es)
PE (1) PE20170201A1 (es)
PH (1) PH12016502540A1 (es)
PL (1) PL3166596T3 (es)
PT (1) PT3166596T (es)
SG (1) SG11201610227TA (es)
SI (1) SI3166596T1 (es)
TN (1) TN2016000557A1 (es)
TW (1) TWI707682B (es)
WO (1) WO2016005880A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3097281A1 (en) 2018-05-03 2019-11-07 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191487A1 (en) 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
MX2009009703A (es) * 2007-03-13 2010-03-03 Takeda Pharmaceutical Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo.
SI2523731T1 (sl) * 2010-01-14 2019-02-28 Novartis Ag Uporaba sredstva, ki modificira adrenalni hormon
NZ607494A (en) * 2010-08-27 2015-04-24 Vertex Pharma Pharmaceutical composition and administrations thereof
US9370505B2 (en) * 2011-09-08 2016-06-21 Mereo Biopharma 2 Limited Pharmaceutical compositions comprising an aromatse inhibitors
PL2804863T3 (pl) * 2012-01-17 2016-06-30 Novartis Ag Nowe postacie i sole inhibitora syntazy aldosteronowej lub aromatazy dihydropirolo[1,2-c]imidazolilu
WO2013126326A1 (en) 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, compositions and methods of use thereof
US9333234B2 (en) * 2012-04-12 2016-05-10 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern

Also Published As

Publication number Publication date
PH12016502540A1 (en) 2017-04-10
KR20170029491A (ko) 2017-03-15
MX2016017315A (es) 2017-04-27
JP2019194221A (ja) 2019-11-07
AR101116A1 (es) 2016-11-23
CL2017000026A1 (es) 2017-07-28
CN106470704B (zh) 2020-07-31
BR112016030243B1 (pt) 2023-04-11
CY1120749T1 (el) 2019-12-11
TW201613586A (en) 2016-04-16
CN106470704A (zh) 2017-03-01
ECSP17008187A (es) 2018-03-31
SI3166596T1 (sl) 2018-10-30
SG11201610227TA (en) 2017-01-27
WO2016005880A1 (en) 2016-01-14
AU2015287336B2 (en) 2018-06-14
US10709691B2 (en) 2020-07-14
AU2015287336A1 (en) 2017-01-12
US20190060283A1 (en) 2019-02-28
US20170202808A1 (en) 2017-07-20
DK3166596T3 (en) 2018-09-10
EA033685B1 (ru) 2019-11-15
EP3166596B1 (en) 2018-06-06
PT3166596T (pt) 2018-10-19
ES2686704T3 (es) 2018-10-19
LT3166596T (lt) 2018-09-25
HRP20181406T1 (hr) 2018-10-19
EP3412278A1 (en) 2018-12-12
EA201991359A1 (ru) 2020-03-13
IL249374B (en) 2021-09-30
BR112016030243A2 (pt) 2017-08-22
CA2954393A1 (en) 2016-01-14
CA2954393C (en) 2022-07-19
JP6731136B2 (ja) 2020-07-29
EA201790140A1 (ru) 2017-05-31
EP3166596A1 (en) 2017-05-17
TWI707682B (zh) 2020-10-21
JP2017520590A (ja) 2017-07-27
KR102468610B1 (ko) 2022-11-21
HUE039037T2 (hu) 2018-12-28
US10143680B2 (en) 2018-12-04
PL3166596T3 (pl) 2018-11-30
IL249374A0 (en) 2017-02-28
TN2016000557A1 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
PH12016501122A1 (en) Delayed release compositions of linaclotide
CL2015002304A1 (es) Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
CL2015002148A1 (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
CR20150455A (es) Imidazopiridazinas sustituidas
IN2013MU03583A (es)
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
PL3003285T3 (pl) Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej
NI201600006A (es) Pirazolo-piridinaminas sustituidas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
BR112014031706A8 (pt) Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
CL2013003588A1 (es) Composicion farmaceutica en forma de suspension oral que comprende como principio activo una fraccion de flavonoide y como excipiente goma de xantano en la cantidad de 0,30 %p/p a 0,60 %p/p; uso para el tratamiento de la insuficiencia venosa.
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
CL2016000397A1 (es) Tratamiento contra el cáncer
PE20170201A1 (es) Formas de dosificacion farmaceutica
MX2017007856A (es) Composicion para el cuidado bucal.
EA201500694A1 (ru) Монолитная лекарственная форма для модифицированного высвобождения комбинации активных ингредиентов
CO2017000354A2 (es) Desmopresina estabilizada

Legal Events

Date Code Title Description
FD Application declared void or lapsed